Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

C4 Therapeutics (CCCC) Return on Capital Employed (2020 - 2025)

C4 Therapeutics (CCCC) has 6 years of Return on Capital Employed data on record, last reported at 0.41% in Q4 2025.

  • For Q4 2025, Return on Capital Employed fell 4.0% year-over-year to 0.41%; the TTM value through Dec 2025 reached 0.41%, down 4.0%, while the annual FY2025 figure was 0.36%, 2.0% up from the prior year.
  • Return on Capital Employed reached 0.41% in Q4 2025 per CCCC's latest filing, up from 0.53% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.18% in Q4 2021 and bottomed at 0.53% in Q3 2025.
  • Average Return on Capital Employed over 5 years is 0.34%, with a median of 0.36% recorded in 2023.
  • Peak YoY movement for Return on Capital Employed: fell -21bps in 2023, then increased 8bps in 2024.
  • A 5-year view of Return on Capital Employed shows it stood at 0.18% in 2021, then crashed by -79bps to 0.32% in 2022, then plummeted by -38bps to 0.45% in 2023, then rose by 16bps to 0.38% in 2024, then dropped by -10bps to 0.41% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Capital Employed were 0.41% in Q4 2025, 0.53% in Q3 2025, and 0.47% in Q2 2025.